Literature DB >> 10526199

Medial temporal lobe metabolic impairment in dementia associated with motor neuron disease.

G Garraux1, E Salmon, C Degueldre, C Lemaire, G Franck.   

Abstract

In the course of their disease certain patients with frontotemporal dementia (FTD) develop clinical features compatible with a motor neuron disease (FTD-MND). Previous reports have suggested that the functional pattern is similar in FTD and FTD-MND. However, some neuropathological studies suggest greater involvement of medial temporal regions in FTD-MND than in FTD. Using statistical parametric mapping (SPM96), we compared the metabolic patterns obtained at rest with positron emission tomography in 10 FTD patients and three FTD-MND patients with those obtained from 46 healthy subjects (HS). Mean age, duration of illness and dementia stage did not differ statistically between the FTD and FTD-MND groups. In comparison with HS, both groups showed frontal and anterior temporal hypometabolism at P<0.001. When the FTD-MND group was compared to the FTD group, significant hypometabolism was only observed in bilateral amygdala, bilateral hippocampus, and bilateral enthorinal and parahippocampal regions (Brodmann's areas, BA 28/36) at P<0.005. We found no significant differences in regional glucose uptake when FTD patients were contrasted to FTD-MND patients. Our results suggest statistically comparable frontal and lateral temporal hypometabolism in both conditions but greater impairment of medial temporal lobe activity in FTD-MND. Our results and a review of the literature support the hypothesis that there is a functional continuum between classical motor neuron disease (cMND), FTD-MND, and FTD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10526199     DOI: 10.1016/s0022-510x(99)00188-4

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  MRI signatures of brain macrostructural atrophy and microstructural degradation in frontotemporal lobar degeneration subtypes.

Authors:  Yu Zhang; Maria Carmela Tartaglia; Norbert Schuff; Gloria C Chiang; Christopher Ching; Howard J Rosen; Maria Luisa Gorno-Tempini; Bruce L Miller; Michael W Weiner
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

2.  Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis.

Authors:  Johannes Brettschneider; David J Libon; Jon B Toledo; Sharon X Xie; Leo McCluskey; Lauren Elman; Felix Geser; Virginia M Y Lee; Murray Grossman; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2012-01-01       Impact factor: 17.088

3.  Pathophysiology of the behavioral variant of frontotemporal lobar degeneration: A study combining MRI and FDG-PET.

Authors:  M-S Buhour; F Doidy; M Laisney; A L Pitel; V de La Sayette; F Viader; F Eustache; B Desgranges
Journal:  Brain Imaging Behav       Date:  2017-02       Impact factor: 3.978

Review 4.  Neuroimaging biomarkers of neurodegenerative diseases and dementia.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

Review 5.  Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease.

Authors:  Federica Agosta; Daniele Altomare; Cristina Festari; Stefania Orini; Federica Gandolfo; Marina Boccardi; Javier Arbizu; Femke Bouwman; Alexander Drzezga; Peter Nestor; Flavio Nobili; Zuzana Walker; Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-01       Impact factor: 9.236

Review 6.  Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.

Authors:  Zuzana Walker; Federica Gandolfo; Stefania Orini; Valentina Garibotto; Federica Agosta; Javier Arbizu; Femke Bouwman; Alexander Drzezga; Peter Nestor; Marina Boccardi; Daniele Altomare; Cristina Festari; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-19       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.